HC Wainwright Issues Optimistic Forecast for DVAX Earnings

Dynavax Technologies Co. (NASDAQ:DVAX) – Equities research analysts at HC Wainwright boosted their FY2026 earnings estimates for shares of Dynavax Technologies in a research note issued on Friday, February 21st. HC Wainwright analyst E. White now forecasts that the biopharmaceutical company will post earnings per share of $0.54 for the year, up from their prior forecast of $0.45. HC Wainwright has a “Buy” rating and a $31.00 price objective on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Dynavax Technologies’ FY2027 earnings at $0.69 EPS.

Several other analysts have also recently weighed in on DVAX. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st. StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday. Finally, The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th.

Dynavax Technologies Price Performance

Shares of DVAX stock opened at $13.41 on Monday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The firm has a market cap of $1.76 billion, a P/E ratio of 74.50 and a beta of 1.32. The business’s 50 day moving average price is $12.83 and its 200-day moving average price is $12.06. Dynavax Technologies has a fifty-two week low of $9.74 and a fifty-two week high of $14.05.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.05. The company had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%.

Hedge Funds Weigh In On Dynavax Technologies

A number of institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in shares of Dynavax Technologies during the 4th quarter valued at $35,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Dynavax Technologies by 37.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 420,325 shares of the biopharmaceutical company’s stock valued at $5,368,000 after acquiring an additional 113,872 shares during the period. Woodline Partners LP boosted its stake in Dynavax Technologies by 2.2% during the fourth quarter. Woodline Partners LP now owns 794,475 shares of the biopharmaceutical company’s stock worth $10,145,000 after acquiring an additional 17,156 shares in the last quarter. Squarepoint Ops LLC grew its holdings in Dynavax Technologies by 509.3% in the fourth quarter. Squarepoint Ops LLC now owns 124,807 shares of the biopharmaceutical company’s stock worth $1,594,000 after purchasing an additional 104,325 shares during the period. Finally, Two Sigma Investments LP increased its stake in shares of Dynavax Technologies by 9.0% during the fourth quarter. Two Sigma Investments LP now owns 866,356 shares of the biopharmaceutical company’s stock valued at $11,063,000 after purchasing an additional 71,575 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.